Biotech · Private company
Repros Therapeutics Inc.
Track this companyFree. Adds Repros Therapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- EnclomiphenePhase 2 · Acquired Hypogonadotropic HypogonadismClinicalTrials.gov · fetched Nov 12, 2026
- Proellex®Phase 2 · EndometriosisClinicalTrials.gov · fetched Nov 12, 2026
- Proellex®Phase 2 · Uterine FibroidsClinicalTrials.gov · fetched Nov 12, 2026
- Telapristone acetatePhase 2 · Uterine FibroidsClinicalTrials.gov · fetched Nov 12, 2026
- Telapristone acetatePhase 2 · EndometriosisClinicalTrials.gov · fetched Nov 12, 2026
- 12.5 mg Androxal Formulation APhase 1 · BioequivalenceClinicalTrials.gov · fetched Nov 12, 2026
- 12.5 mg Androxal Formulation BPhase 1 · BioequivalenceClinicalTrials.gov · fetched Nov 12, 2026
- 25 mg Androxal Formulation APhase 1 · BioequivalenceClinicalTrials.gov · fetched Nov 12, 2026
- 25 mg Androxal Formulation BPhase 1 · BioequivalenceClinicalTrials.gov · fetched Nov 12, 2026
- ProellexPhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- Proellex 25 mg formulation APhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Proellex 25 mg formulation BPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsPHASE2 · TERMINATED · started Jul 26, 2016ClinicalTrials.gov NCT02811159 · fetched Nov 12, 2026
- A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg EnclomiphenePHASE2 · COMPLETED · started Jan 11, 2016ClinicalTrials.gov NCT02651688 · fetched Nov 12, 2026
- A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine FibroidsPHASE2 · COMPLETED · started Mar 16, 2015ClinicalTrials.gov NCT02301897 · fetched Nov 12, 2026
- Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine FibroidsPHASE2 · COMPLETED · started Feb 12, 2015ClinicalTrials.gov NCT02323646 · fetched Nov 12, 2026
- Comparison of Two Formulations of AndroxalPHASE1 · COMPLETED · started Dec 31, 2013ClinicalTrials.gov NCT01984398 · fetched Nov 12, 2026
- Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic EndometriosisPHASE2 · COMPLETED · started May 2, 2013ClinicalTrials.gov NCT01728454 · fetched Nov 12, 2026
- Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension StudyPHASE2 · TERMINATED · started Feb 28, 2009ClinicalTrials.gov NCT00958412 · fetched Nov 12, 2026
- Crossover Study of the Safety and PK Properties of Proellex®PHASE1 · COMPLETED · started Aug 11, 2008ClinicalTrials.gov NCT00749879 · fetched Nov 12, 2026
- Proellex® Pharmacokinetic Bridging Study IIPHASE1 · COMPLETED · started Feb 29, 2008ClinicalTrials.gov NCT00620503 · fetched Nov 12, 2026
- Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003PHASE2 · COMPLETED · started Sep 7, 2006ClinicalTrials.gov NCT00958334 · fetched Nov 12, 2026